In this Review, we discuss the role of bispecific antibodies in patients with cancer, including history and development, as well as innovative targeting strategies, clinical applications, and adverse events. We also discuss novel alternative bispecific antibody constructs, such as those targeting two ...
This review initially delves into specific design considerations for BsADCs, encompassing target selection, antibody formats, and the linker–payload complex. Subsequent sections delineate the extant progress and challenges encountered by BsADCs, illustrated through pertinent case studies. The amalgamation of...
OA-05 efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): analysis of patient and disease-related factors associated with responses Clin Lymph, Myel Leuke, 23 (2023), pp. S3-S4 View PDFView articleGoogle Scholar 15 Kumar S...
Blood Cancer Journal www.nature.com/bcj REVIEW ARTICLE OPEN Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel Noopur Raje 1 ✉, Kenneth Anderson 2, Hermann Einsele 3, Yvonne Efebera4, ...
Review, we discuss the role of bispecific antibodies in patients with cancer, including history and development, as well as innovative targeting strategies, clinical applications, and adverse events. We also discuss novel alternative bispecific antibody constructs, such as those targeting two antigens ...
Cibisatamab is a bispecific antibody-based construct targeting carcinoembryonic antigen (CEA) on tumour cells and CD3 epsilon chain as a T-cell engager. Here we evaluated cibisatamab for advanced CEA-positive solid tumours in two open-label Phase 1 dose-
Advances in protein engineering technology have generated multiple bispecific antibody (BsAb) formats capable of targeting multiple antigens as a single agent. Approval of two BsAb and three check point blocking mAbs represent a paradigm shift in the use of antibody constructs. Since BsAbs can ...
双特异性抗体(Bispecific Antibody,双抗),是指一个抗体分子可以与两个不同抗原或同一抗原的两个不同抗原表位相结合。截止2019年9月,全球共有120种双抗处于临床研发阶段,处于临床前研究阶段的双抗接近200种。 (一)多抗与单抗的区别 双抗可谓两种单抗的混合物,具备典型的多抗特征。从多抗与单抗的区别分析,制备方...
Review article Bispecific antibodies for the treatment of neuroblastoma Pharmacology & Therapeutics Journal 2022,Pharmacology & Therapeutics MadelynEspinosa-Cotton,Nai-Kong V.Cheung Abstract Bispecific antibodies (BsAb) are a new generation of antibody-based therapy, conveying artificial specificity to polyclona...
3. Bispecific antibody formats and modifications 4. Engagement of immune cells 5. Payload delivery 6. Signaling blockade 7. Remaining challenges 8. Conclusion Conflict of interest statement Appendix A. Supplementary data ReferencesShow full outline Cited by (222) Figures (4) Tables (3) Table 1 ...